↓ Skip to main content

Dove Medical Press

Article Metrics

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Overview of attention for article published in Biologics: Targets & Therapy, December 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
20 Mendeley
Title
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
Published in
Biologics: Targets & Therapy, December 2017
DOI 10.2147/btt.s108818
Pubmed ID
Authors

Hanford Yau, Mustafa Kinaan, Suzanne L Quinn, Andreas G Moraitis

Abstract

Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide's efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 20%
Other 3 15%
Student > Postgraduate 2 10%
Student > Bachelor 2 10%
Student > Ph. D. Student 2 10%
Other 2 10%
Unknown 5 25%
Readers by discipline Count As %
Medicine and Dentistry 6 30%
Pharmacology, Toxicology and Pharmaceutical Science 3 15%
Economics, Econometrics and Finance 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Physics and Astronomy 1 5%
Other 1 5%
Unknown 7 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2017.
All research outputs
#9,794,431
of 12,259,388 outputs
Outputs from Biologics: Targets & Therapy
#136
of 196 outputs
Outputs of similar age
#245,186
of 342,738 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 3 outputs
Altmetric has tracked 12,259,388 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 196 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,738 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.